Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients

Background. Short-term studies have suggested that sevelamer hydrochloride, a non-aluminium- and non-calcium-containing hydrogel, is an effective phosphate binder in haemodialysis patients, and may produce favourable changes in the lipid profile. Methods. To determine the long-term effectiveness of...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 1999-12, Vol.14 (12), p.2907-2914
Main Authors: Chertow, Glenn M., Burke, Steven K., Dillon, Maureen A., Slatopolsky, Eduardo
Format: Article
Language:English
Subjects:
calcium
cholesterol
end-stage renal disease
haemodialysis
hyperparathyroidism
hyperphosphataemia
phosphate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Short-term studies have suggested that sevelamer hydrochloride, a non-aluminium- and non-calcium-containing hydrogel, is an effective phosphate binder in haemodialysis patients, and may produce favourable changes in the lipid profile. Methods. To determine the long-term effectiveness of sevelamer hydrochloride, we performed an open-label clinical trial in 192 adult patients with end-stage renal disease on haemodialysis. Drug-related changes in the concentrations of serum phosphorus, calcium, calcium×phosphate product, parathyroid hormone, and low- and high-density lipoprotein cholesterol concentrations were the major outcomes of interest. Results. Treatment with sevelamer was associated with a mean change in serum phosphorus of −0.71±0.77 mmol/l, serum calcium of 0.08±0.22 mmol/l, and calcium×phosphate product of −1.46±1.78 mmol/l (P
ISSN:0931-0509
1460-2385
DOI:10.1093/ndt/14.12.2907